Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation

Age in years (median, range) 45 (10-46) 32(13-56) .83 Conditioning regimen Myeloablative 4/5 (80%) 8/10 (80%) 1.0 Reduced intensity 1/5 (20%) 2/10 (20%) 1.0 aGVHD 1/5 (20%) 7/10 (70%) .12 Grade II-IV aGVHD 1/5 (20%) 1/10 (10%) 1.0 cGVHD 4/5 (80%) 8/10 (80%) 1.0 Extensive cGVHD 1/5 (20%) 1/10 (10%) 1.0 IST for cGVHD >3 years 3/5 (60%) 5/10 (50%) 1.0 Lamivudine treatment 3/5 (60%) — Lamivudine prophylaxis* 0 5/10 (50%) HBV vaccine after SCT 0 6/10 (60%) Donors with vaccination of HBV 1/5 (20%) 1/10 (10%) 1.0